Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy
Burgard C, Khreish F, Dahlmanns L, Blickle A, Bastian MB, Speicher T, Maus S, Schaefer-Schuler A, Bartholomä M, Petto S, Ezziddin S, Rosar F (2024)
Publication Type: Journal article
Publication year: 2024
Journal
Book Volume: 16
Article Number: 3532
Journal Issue: 20
Abstract
Augmentation of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) by alpha emitting 225Ac, known as the tandem therapy concept, is a promising escalating treatment option in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to analyze the value of imaging parameters in baseline [18F]FDG PET/CT for predicting response and outcome to PSMA tandem RLT in patients with insufficient response to the initial [177Lu]Lu-PSMA-617 monotherapy. The quantitative whole-body imaging biomarker total lesion glycolysis (TLG) was identified as a prognostic biomarker for overall survival (OS), while response could not be predicted by any of the tested parameters. Using [18F]FDG PET/CT in clinical practice could help predict outcomes and may provide more personalized care for mCRPC patients.
Involved external institutions
Germany (DE)How to cite
APA:
Burgard, C., Khreish, F., Dahlmanns, L., Blickle, A., Bastian, M.B., Speicher, T.,... Rosar, F. (2024). Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy. Cancers, 16(20). https://doi.org/10.3390/cancers16203532
MLA:
Burgard, Caroline, et al. "Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy." Cancers 16.20 (2024).
BibTeX: Download